Data / New clinical trials / Lymphoma, Large B-Cell, Diffuse

Lymphoma, Large B-Cell, Diffuse trials: 169 new

Name: New Lymphoma, Large B-Cell, Diffuse clinical trials
Creator: SpecStream
License: https://creativecommons.org/licenses/by/4.0/

The full list. New Lymphoma, Large B-Cell, Diffuse clinical trials: 169 rows for $8.45, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. The list gains about 8 rows a month. The new rows come each week by email, $19 a month.

Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, enrollment type, location countries and 5 more), which open on your screen as soon as the payment clears and come by email. The weekly rows run until you cancel, from the link in each delivery. The rows on this page are a sample.

For agents and scripts: this list is ordered at https://specstream.ai/data/clinical-trials/condition/lymphoma-large-b-cell-diffuse, and every list with its row count and price is at https://specstream.ai/data/lists.json.

Updated November 5, 2026. Source: ClinicalTrials.gov API v2 (U.S. National Library of Medicine).

169 clinical studies in Lymphoma, Large B-Cell, Diffuse were first posted on ClinicalTrials.gov from November 12, 2024 to November 5, 2026; 46 have an industry sponsor and 146 are recruiting or about to. The newest, NCT07917754, was posted on November 5, 2026: A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma... (Merck Sharp & Dohme LLC).

The request: Every new Lymphoma, Large B-Cell, Diffuse clinical trial on ClinicalTrials.gov, with the sponsor, phase, sites and the listed contact. $10 of credit on sign-up, no card.

Get new trials like these Watch a sponsor

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

169New trials
46Industry sponsored
146Recruiting or not yet
November 5, 2026Latest posted

Newest trials

The newest 100 of 169, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

First posted	NCT ID	Title	Sponsor	Phase	Status	Conditions	Enrollment	Countries	Source
November 5, 2026	NCT07917754	A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)	Merck Sharp & Dohme LLC	Phase 2/3	Not yet recruiting	Lymphoma, Large B-Cell, Diffuse, Diffuse Large B-Cell Lymphoma	470		clinicaltrials.gov
November 4, 2026	NCT07917624	Prophylactic Strategies for Mitigating Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Phase 2	Not yet recruiting	Diffuse Large B-Cell Lymphoma (DLBCL)	87	China	clinicaltrials.gov
November 2, 2026	NCT07908888	Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in...	The First Hospital of Jilin University	Phase 4	Recruiting	Diffuse Large B-Cell Lymphoma	26	China	clinicaltrials.gov
October 30, 2026	NCT07906080	Study to Evaluate the Feasibility and Safety of Autologous Cytokine-Induced Killer Cells (CIK_D332) in Combination With Tafasitamab and...	Istituto Oncologico Veneto IRCCS	Phase 1	Not yet recruiting	Diffuse Large B-Cell Lymphoma (DLBCL)	14	Italy	clinicaltrials.gov
October 23, 2026	NCT07892027	Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma...	University of Michigan Rogel Cancer Center	Phase 2	Recruiting	Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma...	26	United States	clinicaltrials.gov
October 21, 2026	NCT07887750	REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)	Regeneron Pharmaceuticals	Phase 1/2	Not yet recruiting	Diffuse Large B-Cell Lymphoma (DLBCL)	36		clinicaltrials.gov
October 21, 2026	NCT07887646	A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0920 Works in Adults With Diffuse Large B-cell...	BeOne Medicines	Phase 1	Not yet recruiting	Diffuse Large B-Cell Lymphoma, B-cell Malignancies	70		clinicaltrials.gov
October 20, 2026	NCT07883941	Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid...	GUSTAVO SALGUERO	Phase 1	Not yet recruiting	Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies, Diffuse Large B Cell Lymphoma...	12		clinicaltrials.gov
October 19, 2026	NCT07881211	A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0050 Works in Adults With Diffuse Large B-cell...	BeOne Medicines	Phase 1	Not yet recruiting	Diffuse Large B-Cell Lymphoma, B-Cell Malignancies	70		clinicaltrials.gov
October 16, 2026	NCT07878351	Prospective ctDNA Testing in Large B-Cell Lymphoma	Peking University People's Hospital	Observational	Recruiting	Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma	100	China	clinicaltrials.gov
October 15, 2026	NCT07875413	Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell...	AbelZeta Inc.	Phase 2	Not yet recruiting	Large B Cell Lymphoma, LBCL, Diffuse Large B Cell Lymphoma (DLBCL), Relapse Diffuse Large B Cell Lymphoma, High Grade B...	55	United States	clinicaltrials.gov
October 7, 2026	NCT07862764	A Study to Assess Change in Disease State and Adverse Events in Korean Adult Patients With Relapsed or Refractory Diffuse Large B-Cell...	AbbVie	Observational	Not yet recruiting	Diffuse Large B-Cell Lymphoma	175		clinicaltrials.gov
September 14, 2026	NCT07818499	A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma	Sichuan Baili Pharmaceutical Co., Ltd.	Phase 1/2	Not yet recruiting	Diffuse Large B-Cell Lymphoma	204	China	clinicaltrials.gov
September 14, 2026	NCT07817641	Proton Therapy for Mediastinal Lymphoma (PROMLY)	Copenhagen University Hospital, Rigshospitalet	Not applicable	Recruiting	Mediastinal Lymphoma, Hodgkin Disease Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL)	139	Denmark	clinicaltrials.gov
September 10, 2026	NCT07814170	A Manualised Post-Traumatic Growth Intervention For People With Hematological Cancers In Greece	University of West Attica	Not applicable	Active not recruiting	Blood Cancers, Leukemia, Lymphoma, Bone Marrow Transplant, Psychological Trauma, Neoplasms, Hematological Malignancies...	80	Greece	clinicaltrials.gov
September 10, 2026	NCT07814001	Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy	The Lymphoma Academic Research Organisation	Phase 2	Not yet recruiting	Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Refractory Large B-cell Lymphoma (LBCL), Refractory...	55	France	clinicaltrials.gov
September 9, 2026	NCT07808827	A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients...	Shanghai Junshi Bioscience Co., Ltd.	Phase 3	Recruiting	Diffuse Large B-Cell Lymphoma	282	China	clinicaltrials.gov
September 4, 2026	NCT07804173	Tumour Immune and Ki-67 Scoring Methods as Prognostic Biomarkers in Diffuse Large B-cell Lymphoma and Aggressive B-cell Lymphomas	Sohag University	Observational	Not yet recruiting	Diffuse Large B-cell Lymphoma and Aggressive B-cell Lymphomas	70	Egypt	clinicaltrials.gov
August 26, 2026	NCT07788118	A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma	Second Affiliated Hospital, Zhejiang University, School of Medicine	Phase 1/2	Recruiting	Relapsed/Refractory Large B-cell Lymphoma (LBCL), Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large...	70	China	clinicaltrials.gov
August 19, 2026	NCT07774234	Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma	The First Affiliated Hospital of Soochow University	Phase 2	Not yet recruiting	Large B-Cell Lymphoma (LBCL), High-grade B-cell Lymphoma	39	China	clinicaltrials.gov
August 14, 2026	NCT07764601	R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma	WEI XU	Not applicable	Not yet recruiting	Primary Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma	58	China	clinicaltrials.gov
August 13, 2026	NCT07763210	Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma	Vanderbilt-Ingram Cancer Center	Phase 2	Recruiting	Non-hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell...	59	United States	clinicaltrials.gov
August 12, 2026	NCT07760610	Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly Diagnosed DLBCL After First-Line Response	The First Hospital of Jilin University	Phase 4	Not yet recruiting	Diffuse Large B-Cell Lymphoma (DLBCL)	27		clinicaltrials.gov
August 6, 2026	NCT07750886	Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)	Natera, Inc.	Observational	Recruiting	Non-Hodgkin Lymphoma, T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, High-Grade B-Cell Lymphoma, Primary Mediastinal...	200	United States	clinicaltrials.gov
August 6, 2026	NCT07749976	GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors	Vitruviae	Phase 1/2	Not yet recruiting	Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL), High Risk Myelodysplastic Syndrome, Solid Tumor...	108		clinicaltrials.gov
August 5, 2026	NCT07748364	Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics	Joshua Brody	Phase 2	Not yet recruiting	Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Mantle Cell Lymphoma	16	United States	clinicaltrials.gov
July 30, 2026	NCT07735533	A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies	Umoja Biopharma	Phase 1/2	Recruiting	Lymphoma, B Cell, Lymphoma Non-Hodgkin, High Grade B Cell Lymphoma, Richter Transformation Lymphoma, Grade 3b...	274	United States	clinicaltrials.gov
July 27, 2026	NCT07729397	Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)	The Methodist Hospital Research Institute	Phase 1	Not yet recruiting	Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL), Anaplastic Large Cell...	21	United States	clinicaltrials.gov
July 24, 2026	NCT07725406	Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma	Weill Medical College of Cornell University	Phase 1	Recruiting	Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM)	32	United States	clinicaltrials.gov
July 20, 2026	NCT07714421	Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients	Jonsson Comprehensive Cancer Center	Phase 1	Not yet recruiting	Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, Primary Mediastinal Large...	20	United States	clinicaltrials.gov
July 20, 2026	NCT07713459	A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	Kure Cells, INC	Phase 2	Not yet recruiting	Lymphoma Nonhodgkin, Marginal Zone B Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Follicular B-cell...	105		clinicaltrials.gov
July 17, 2026	NCT07712588	Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)	Dizal Pharmaceuticals	Phase 2/3	Not yet recruiting	Diffuse Large B-Cell Lymphoma (DLBCL)	880	China	clinicaltrials.gov
July 14, 2026	NCT07702851	A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After...	Yonsei University	Phase 2	Not yet recruiting	Diffuse Large B-cell Lymphoma	47		clinicaltrials.gov
July 9, 2026	NCT07691606	A Study of ARC-02 in B-cell NHL	Taiho Oncology, Inc.	Phase 1	Recruiting	B-cell Non Hodgkin Lymphoma	140	Australia, France, Italy, Poland, Spain, United States	clinicaltrials.gov
June 30, 2026	NCT07676877	Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent...	Nathan Denlinger	Phase 1	Recruiting	Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma	18	United States	clinicaltrials.gov
June 25, 2026	NCT07669194	Glofitamab Combined With Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma	Second Affiliated Hospital, Zhejiang University, School of Medicine	Observational	Not yet recruiting	Diffuse Large B-Cell Lymphoma (DLBCL)	30	China	clinicaltrials.gov
June 17, 2026	NCT07654426	The CARDIOPROTECT Trial	Beth Israel Deaconess Medical Center	Phase 2	Not yet recruiting	Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma	60	United States	clinicaltrials.gov
June 17, 2026	NCT07652476	Neurocognitive Assessment in Long-Term Survivors of Lymphoma	Fondazione Italiana Linfomi - ETS	Observational	Not yet recruiting	Classic Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal B Cell Lymphoma	100	Italy	clinicaltrials.gov
June 16, 2026	NCT07649304	AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")	National Cancer Institute (NCI)	Phase 1	Recruiting	AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell...	15	United States	clinicaltrials.gov
June 10, 2026	NCT07638982	Axatilimab + CAR-T for High-Risk Lymphoma	Northside Hospital, Inc.	Phase 1	Not yet recruiting	Diffuse Large B Cell Lymphoma (DLBCL), Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell...	29	United States	clinicaltrials.gov
June 8, 2026	NCT07634289	Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma	Olivia Newton-John Cancer Research Institute	Phase 2	Not yet recruiting	Relapsed /Refractory DLBCL	40	Australia	clinicaltrials.gov
June 2, 2026	NCT07621406	Efficacy and Safety of Sequential Autologous Hematopoietic Stem Cell Transplantation Combined With Tafasitamab, Lenalidomide, and Standard...	The First Affiliated Hospital of Soochow University	Phase 2	Active not recruiting	Relapsed/Refractory Diffuse Large B Cell Lymphoma	25	China	clinicaltrials.gov
May 27, 2026	NCT07609862	A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies	Guangzhou Lupeng Pharmaceutical Company LTD.	Phase 1/2	Recruiting	Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL), Waldenström...	92	China	clinicaltrials.gov
May 27, 2026	NCT07608978	Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in...	The First Affiliated Hospital with Nanjing Medical University	Phase 2	Recruiting	Diffuse Large B-Cell Lymphoma (DLBCL)	35	China	clinicaltrials.gov
May 22, 2026	NCT07601607	Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma	Sun Yat-sen University	Phase 1/2	Not yet recruiting	Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)	51	China	clinicaltrials.gov
May 20, 2026	NCT07599423	A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma	The First Affiliated Hospital of Soochow University	Phase 2	Not yet recruiting	Diffuse Large B Cell Lymphoma (DLBCL)	96	China	clinicaltrials.gov
May 15, 2026	NCT07588698	Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma	Carrie Ho, MD	Phase 2	Not yet recruiting	Non-Hodgkin's B-cell Lymphoma, Lymphoma Non-Hodgkin, Diffuse Large B-Cell Lymphoma (DLBCL)	20	United States	clinicaltrials.gov
May 13, 2026	NCT07583771	A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma	Chipscreen Biosciences, Ltd.	Phase 1	Not yet recruiting	Pancreatic Adenocarcinoma, Non Small Cell Lung Cancer, Advanced Solid Tumors, Lymphoma, Diffuse Large B-Cell Lymphoma...	186	China	clinicaltrials.gov
April 20, 2026	NCT07539688	Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell Lymphoma	Institute of Hematology & Blood Diseases Hospital, China	Phase 1	Not yet recruiting	Relapsed/Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma, Inert B-cell Lymphoma Transformed Into Large B-cell...	18		clinicaltrials.gov
April 14, 2026	NCT07528352	External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL	University of Utah	Phase 1	Recruiting	Diffuse Large B Cell Lymphoma	12	United States	clinicaltrials.gov
April 13, 2026	NCT07523737	Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell...	Beijing Tongren Hospital	Phase 2	Recruiting	Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B Cell Lymphoma (DLBCL)	43	China	clinicaltrials.gov
April 9, 2026	NCT07519772	A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)	Merck Sharp & Dohme LLC	Phase 1/2	Recruiting	Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse	280	Argentina, Australia, Brazil, Canada, Chile, China, France, Germany, Israel...	clinicaltrials.gov
April 8, 2026	NCT07517705	MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma	University of Nebraska	Phase 2	Not yet recruiting	Diffuse Large B-Cell Lymphoma	50	United States	clinicaltrials.gov
April 2, 2026	NCT07507318	Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission	Rong Tao	Phase 2	Recruiting	Diffuse Large B-Cell Lymphoma	69	China	clinicaltrials.gov
March 31, 2026	NCT07502872	TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma	Brown University	Phase 2	Not yet recruiting	Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Lymphoma, Lymphoma, B-Cell	30	United States	clinicaltrials.gov
March 30, 2026	NCT07502118	NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)	Health Institutes of Turkey	Phase 2/3	Recruiting	Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL), Relapsed/Refractory Non-Hodgkin Lymphoma, Diffuse...	40	Turkey (Türkiye)	clinicaltrials.gov
March 30, 2026	NCT07499271	Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation	The First Affiliated Hospital of Soochow University	Phase 2	Recruiting	Diffuse Large B-Cell Lymphoma (DLBCL)	35	China	clinicaltrials.gov
March 27, 2026	NCT07494565	Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL	Sun Yat-sen University	Phase 2	Recruiting	Diffuse Large B-Cell Lymphoma (DLBCL), CD5 Positive	60	China	clinicaltrials.gov
March 25, 2026	NCT07493486	IT-TT as an Effective and Well-Tolerated Strategy for CNS Prop in High-Risk DLBCL: a Prospective Ph II Study	Zhejiang Cancer Hospital	Phase 2	Completed	Diffuse Large B-Cell Lymphoma (DLBCL), Intrathecal Chemotherapy	31	China	clinicaltrials.gov
March 25, 2026	NCT07493148	Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL	Ou Bai, MD/PHD	Phase 2	Recruiting	Diffuse Large B-Cell Lymphoma (DLBCL)	50	China	clinicaltrials.gov
March 25, 2026	NCT07493109	Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP	Ou Bai, MD/PHD	Phase 3	Recruiting	Diffuse Large B-Cell Lymphoma (DLBCL)	200	China	clinicaltrials.gov
March 24, 2026	NCT07489989	Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.	Daihong Liu	Phase 2	Recruiting	Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)	30	China	clinicaltrials.gov
March 18, 2026	NCT07480850	Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Phase 2	Active not recruiting	Refractory Diffuse Large B-Cell Lymphoma (DLBCL)	40	China	clinicaltrials.gov
March 18, 2026	NCT07478848	Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas	Abramson Cancer Center at Penn Medicine	Phase 1	Recruiting	Large B Cell Lymphoma, Non Hodgkin Lymphoma (NHL), Diffuse Large B Cell Lymphoma (DLBCL), Diffuse Large B Cell Lymphoma...	14	United States	clinicaltrials.gov
March 17, 2026	NCT07476105	Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment	Fondazione Italiana Linfomi - ETS	Not applicable	Not yet recruiting	Diffuse Large B Cell Lymphoma, Follicular Lymphoma Grade 3B	170	Italy	clinicaltrials.gov
March 16, 2026	NCT07473167	Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients	TICAROS Co., Ltd.	Phase 1/2	Recruiting	Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), High-grade...	98	South Korea	clinicaltrials.gov
March 11, 2026	NCT07463781	Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy	Fondazione Italiana Linfomi - ETS	Observational	Not yet recruiting	Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma, Primary Mediastinal B-cell Lymphoma (PMBCL)	100	Italy	clinicaltrials.gov
March 5, 2026	NCT07451652	Low Dose Epcoritamab Plus GemOx in R/R DLBCL	Hospital Universitario Dr. Jose E. Gonzalez	Phase 2	Recruiting	Relapsed/Refractory Diffuse Large B Cell Lymphoma	10	Mexico	clinicaltrials.gov
March 2, 2026	NCT07443514	Cognitive Impairment in Patients With Diffuse Large B-Cell Lymphoma	Institute of Oncology Ljubljana	Not applicable	Recruiting	Diffuse Large B-Cell Lymphoma	3	Slovenia	clinicaltrials.gov
February 20, 2026	NCT07424833	A Study of APG-3288 in Relapsed/Refractory Blood Cancers	Ascentage Pharma Group Inc.	Phase 1	Recruiting	Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic...	180	China, United States	clinicaltrials.gov
February 17, 2026	NCT07412405	This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells...	GUSTAVO SALGUERO	Not applicable	Not yet recruiting	Adult B-cell Acute Lymphoblastic Leukemia, Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell...	12		clinicaltrials.gov
February 13, 2026	NCT07409428	A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL	Hutchmed	Phase 3	Recruiting	Relapsed/Refractory Diffuse Large B-Cell Lymphoma	240	China	clinicaltrials.gov
February 10, 2026	NCT07398638	Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study	Sun Yat-sen University	Phase 1/2	Not yet recruiting	Diffuse Large B Cell Lymphoma (DLBCL)	122	China	clinicaltrials.gov
February 9, 2026	NCT07397832	CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL	Tianjin Medical University Cancer Institute and Hospital	Phase 2	Recruiting	Diffuse Large B-Cell Lymphoma (DLBCL)	58	China	clinicaltrials.gov
February 6, 2026	NCT07393204	Italian Real-World Study of Epcoritamab in Relapsed or Refractory DLBCL	Andrés José Maria Ferreri	Observational	Active not recruiting	Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory Diffuse Large B-Cell Lymphoma	150	Italy	clinicaltrials.gov
January 28, 2026	NCT07371923	Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma	Beijing Tongren Hospital	Phase 2	Recruiting	Diffuse Large B Cell Lymphoma (DLBCL)	50	China	clinicaltrials.gov
January 26, 2026	NCT07368270	Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma	Jiangsu Topcel-KH Pharmaceutical Co., Ltd.	Phase 1	Recruiting	Diffuse Large B Cell Lymphoma	30	China	clinicaltrials.gov
January 26, 2026	NCT07365306	Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment...	City of Hope Medical Center	Phase 2	Recruiting	Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma, Not Otherwise...	43	United States	clinicaltrials.gov
January 16, 2026	NCT07348575	A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse...	Second Affiliated Hospital of Nanchang University	Phase 3	Enrolling by invitation	Lymphoma, Large-Cell, Diffuse	80	China	clinicaltrials.gov
December 30, 2025	NCT07310186	Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy	Peking Union Medical College Hospital	Observational	Not yet recruiting	Diffuse Large B Cell Lymphoma (DLBCL)	200		clinicaltrials.gov
December 16, 2025	NCT07284433	Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies	AvenCell Therapeutics, Inc.	Phase 1/2	Recruiting	Lymphoma Diffuse Large B-cell, Leukemia and Lymphoma, Leukemia Relapse, Lymphoma Receiving CAR-T Therapy	178	Germany, United States	clinicaltrials.gov
December 3, 2025	NCT07260812	KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma	TCRx Therapeutics Co.Ltd	Phase 1	Recruiting	Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL)	18	China	clinicaltrials.gov
November 28, 2025	NCT07254754	Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma	Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea	Phase 2	Recruiting	DIFFUSE LARGE B-CELL LYMPHOMA	45	Spain	clinicaltrials.gov
November 12, 2025	NCT07226843	A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers	Eli Lilly and Company	Phase 1	Recruiting	Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma	460	France, Germany, Italy, Japan, Poland, Spain, United Kingdom, United States	clinicaltrials.gov
November 10, 2025	NCT07226752	A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in...	Genmab	Phase 3	Active not recruiting	Diffuse Large B-Cell Lymphoma	72	China	clinicaltrials.gov
November 6, 2025	NCT07225439	Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin...	Paolo Caimi, MD	Phase 1	Recruiting	Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary...	15	United States	clinicaltrials.gov
October 14, 2025	NCT07215832	Karyopharm Expanded Access Program for Selinexor	Karyopharm Therapeutics Inc	Not applicable	Available	Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL), Sarcoma, Neuroglioblastoma, Peripheral T-cell Lymphoma...	Not listed		clinicaltrials.gov
October 1, 2025	NCT07200375	An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma	Hoffmann-La Roche	Observational	Recruiting	Diffuse Large B-Cell Lymphoma	300	China, Hong Kong	clinicaltrials.gov
September 30, 2025	NCT07198230	Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory...	Ting YANG	Observational	Recruiting	Diffuse Large B-Cell Lymphoma, Relapsed and Refractory, Transarterial Chemoembolization	10	China	clinicaltrials.gov
September 29, 2025	NCT07197307	Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)	Universität Münster	Phase 2	Recruiting	Aggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL), Follicular Lymphoma (FL) Grade 3B	120	Germany	clinicaltrials.gov
September 29, 2025	NCT07195916	A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies	Incyte Corporation	Phase 1	Recruiting	Solid Tumors, Hematologic Malignancies	280	Australia, Belgium, Denmark, Italy, United States	clinicaltrials.gov
September 23, 2025	NCT07189065	A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma	Guangzhou Lupeng Pharmaceutical Company LTD.	Phase 2	Recruiting	Diffuse Large B-Cell Lymphoma (DLBCL)	150	China	clinicaltrials.gov
September 23, 2025	NCT07188558	A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy	Lyell Immunopharma, Inc.	Phase 3	Recruiting	Large B-cell Lymphoma, Lymphoma, B-Cell, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin...	400	Australia, Canada, United States	clinicaltrials.gov
September 23, 2025	NCT07188077	Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma	Ting YANG	Observational	Recruiting	Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B-Cell Lymphoma	20	China	clinicaltrials.gov
September 18, 2025	NCT07181785	Molecular Characterization and Outcomes of Aggressive B-Cell Lymphomas.	Andrés José Maria Ferreri	Observational	Completed	Diffuse Large B Cell Lymphoma (DLBCL)	555	Italy	clinicaltrials.gov
September 11, 2025	NCT07168486	CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas	University of Maryland, Baltimore	Phase 1	Enrolling by invitation	B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), Follicular...	15	United States	clinicaltrials.gov
September 11, 2025	NCT07168291	Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma	First Affiliated Hospital Xi'an Jiaotong University	Early phase 1	Not yet recruiting	Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL), Burkitt Lymphoma	3	China	clinicaltrials.gov
September 8, 2025	NCT07159906	Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma	First Affiliated Hospital of Zhejiang University	Phase 1/2	Not yet recruiting	Diffuse Large B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma	62	China	clinicaltrials.gov
August 17, 2025	NCT07126236	Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large...	Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea	Phase 2	Recruiting	Large B Cell Lymphoma	80	Spain	clinicaltrials.gov
August 15, 2025	NCT07124936	A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	Phase 1/2	Recruiting	Diffuse Large B Cell Lymphoma (DLBCL)	97	China	clinicaltrials.gov

Sponsors posting most

Sponsor	New trials	Latest
The First Affiliated Hospital of Soochow University	6	August 19, 2026
Sun Yat-sen University	6	May 22, 2026
Merck Sharp & Dohme LLC	4	November 5, 2026
Second Affiliated Hospital, Zhejiang University, School of Medicine	4	August 26, 2026
Fondazione Italiana Linfomi - ETS	3	June 17, 2026
City of Hope Medical Center	3	January 26, 2026
Ruijin Hospital	3	January 31, 2025
IRCCS Azienda Ospedaliero-Universitaria di Bologna	3	January 20, 2025
Cancer Institute and Hospital, Chinese Academy of Medical Sciences	2	November 4, 2026
The First Hospital of Jilin University	2	November 2, 2026
BeOne Medicines	2	October 21, 2026
GUSTAVO SALGUERO	2	October 20, 2026
AbbVie	2	October 7, 2026
Dizal Pharmaceuticals	2	July 17, 2026
Guangzhou Lupeng Pharmaceutical Company LTD.	2	May 27, 2026
Beijing Tongren Hospital	2	April 13, 2026
Zhejiang Cancer Hospital	2	March 25, 2026
Ou Bai, MD/PHD	2	March 25, 2026
Andrés José Maria Ferreri	2	February 6, 2026
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea	2	November 28, 2025

By phase

Phase	New trials	Latest
Phase 2	65	November 4, 2026
Phase 1	28	October 30, 2026
Observational	26	October 16, 2026
Phase 1/2	21	October 21, 2026
Not applicable	12	September 14, 2026
Phase 3	10	September 9, 2026
Phase 2/3	4	November 5, 2026
Phase 4	2	November 2, 2026
Early phase 1	1	September 11, 2025

By country

Country	New trials	Latest
China	71	November 4, 2026
United States	54	October 23, 2026
Italy	21	October 30, 2026
Australia	9	July 9, 2026
Spain	9	July 9, 2026
France	8	September 10, 2026
Germany	7	April 9, 2026
South Korea	7	April 9, 2026
Poland	6	July 9, 2026
Canada	6	April 9, 2026
United Kingdom	6	April 9, 2026
Japan	5	November 12, 2025
Denmark	4	September 14, 2026
Israel	4	April 9, 2026
Belgium	4	September 29, 2025
Greece	3	September 10, 2026
Argentina	3	April 9, 2026
Turkey (Türkiye)	3	April 9, 2026
Mexico	3	March 5, 2026
Brazil	2	April 9, 2026
Chile	2	April 9, 2026
Hong Kong	2	October 1, 2025
Portugal	2	February 17, 2025
Singapore	2	January 7, 2025
Egypt	1	September 4, 2026

Where the register publishes

U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.